alanine has been researched along with jtk-303 in 35 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 23 (65.71) | 24.3611 |
2020's | 12 (34.29) | 2.80 |
Authors | Studies |
---|---|
Baeten, JM; Wyatt, C | 1 |
Andrade-Villanueva, J; Callebaut, C; Cao, H; Cheng, AK; Crofoot, G; Custodio, JM; DeJesus, E; Fordyce, MW; Koenig, E; Martin, H; McCallister, S; Molina, JM; Oka, S; Plummer, A; Podzamczer, D; Post, F; Pozniak, A; Saag, M; Sax, PE; Thompson, M; Trottier, B; Wohl, D; Yin, MT; Zhong, L | 1 |
Arribas, JR; Brinson, C; Brunetta, J; Callebaut, C; Cheng, A; Cheret, A; Clarke, A; Clumeck, N; Das, M; Fordyce, M; Mussini, C; Oka, S; Rashbaum, B; Sax, PE; Stephens, J; Tashima, K; Tebas, P; Wohl, D; Zhong, L | 1 |
Callebaut, C; Fordyce, M; Kitrinos, KM; Margot, NA; McCallister, S; Miller, MD | 1 |
Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S | 1 |
Deeks, ED; Greig, SL | 1 |
Jones, R; Levy, JB; Milburn, J | 1 |
Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L | 1 |
Destache, CJ; Fan, W; Kang, G; Li, Q; Mandal, S; Prathipati, PK; Yuan, Z; Zhou, Y | 1 |
Arribas, JR; Callebaut, C; Cheng, A; Clarke, AE; Das, M; DeJesus, E; Guo, S; Haas, B; McCallister, S; McDonald, C; Plummer, A; Sax, PE; Thompson, M; Wang, H; Wohl, DA | 1 |
Ikushima, I; Irie, S; Ishikawa, T; Nemoto, T; Ninomiya, N; Yamada, H | 1 |
Baldelli, S; Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Giacomelli, A; Mazzali, C; Meraviglia, P; Milazzo, L; Minisci, D; Resnati, C; Rizzardini, G | 1 |
DeJesus, E; Haas, B; Liu, YP; Makadzange, T; Margot, N; McCallister, S; Mills, A; Ramgopal, MN; Segal-Maurer, S | 1 |
Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Kido, A; Kityo, C; Kulkarni, R; Squires, K | 1 |
Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N | 1 |
Andreoni, M; Cerva, C; Maffongelli, G; Malagnino, V; Sarmati, L; Teti, E | 1 |
Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM | 1 |
Capetti, AF; Cossu, MV; Giacomet, V; Rizzardini, G; Zuccotti, G | 1 |
Kaplun, O; Psevdos, G | 1 |
Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A | 1 |
Burgi, A; Letendre, SL; Little, SJ; Ma, Q; Morse, GD; Ocque, AJ; Sanders, C | 1 |
Castagna, A; Gianotti, N | 1 |
Das, M; Haubrich, R; Maggiolo, F; Mateo-Garcia, MG; McNicholl, I; Molina, JM; Ong, E; Piontkowsky, D; Pulido, F; Raffi, F; Rizzardini, G; Shao, Y | 1 |
Hollenbeck, BL; Kishore, S; Lee, MSL; Padival, S | 1 |
Ajana, F; Bani-Sadr, F; Bouvet, E; Cotte, L; Galempoix, JM; Gantner, P; Hessamfar, M; Hustache-Mathieu, L; Lebrette, MG; Muret, P; Pellissier, G; Piroth, L; Rey, D; Rouveix, E; Simon, A; Souala, MF; Truchetet, F; Valin, N | 1 |
Chuang, YC; Hung, CC; Kuo, PH; Liu, WC; Sun, HY; Wu, PY | 1 |
Chang, SF; Chang, SY; Chen, GJ; Cheng, CY; Chuang, YC; Hsieh, MH; Huang, SH; Hung, CC; Lee, CH; Lee, YC; Lee, YL; Su, LS; Sun, HY; Tang, HJ; Tsai, HC | 1 |
DeMarais, P; Max, B | 1 |
Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ | 1 |
Ma, R; Tong, ZW; Xu, B; Zhang, Q; Zhang, YS; Zhao, CS; Zhao, RG | 1 |
Castagna, A; Esser, S; Haubrich, R; Llibre, JM; Margot, N; McNicholl, IR; Molina, JM; Perez-Valero, I; Piontkowsky, D; Pulido, F; Shao, Y; Temme, L | 1 |
Gao, LY; Hu, Y; Huang, XJ; Ma, P; Wu, H; Wu, Y; Xia, H; Yan, ZF | 1 |
Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
Agrahari, V; Clark, MR; Dinh, C; Doncel, GF; García-Lerma, JG; Heneine, W; Holder, A; Makarova, N; Mendoza, M; Mitchell, J; Pan, Y; Peet, MM; Singletary, T; Smith, JM | 1 |
Anderson, PL; Bushman, LR; Clark, M; Doncel, GF; Fang, X; Hanif, H; Ouattara, LA; Singh, O; Thurman, AR; Yousefieh, N | 1 |
3 review(s) available for alanine and jtk-303
Article | Year |
---|---|
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Child; Cobicistat; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir; United States; United States Food and Drug Administration | 2019 |
13 trial(s) available for alanine and jtk-303
Article | Year |
---|---|
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Headache; HIV Infections; Humans; Kidney; Male; Nausea; Organophosphonates; Quinolones; Respiration Disorders; Sleep Initiation and Maintenance Disorders; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2015 |
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Proteinuria; Quinolones; RNA, Viral; Tenofovir | 2016 |
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tenofovir; Young Adult | 2016 |
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir; Treatment Outcome | 2016 |
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Child; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Quinolones; RNA, Viral; South Africa; Tablets; Tenofovir; Thailand; Uganda; United States; Viral Load | 2016 |
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Middle Aged; Quinolones; Tenofovir; Treatment Outcome; United States | 2017 |
Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.
Topics: Adenine; Administration, Oral; Adult; Alanine; Anti-HIV Agents; Asian People; Breakfast; Cobicistat; Cross-Over Studies; Dietary Proteins; Dietary Supplements; Emtricitabine; Fasting; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Quinolones; Tenofovir | 2018 |
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney; Quinolones; RNA, Viral; Tenofovir; Treatment Outcome | 2018 |
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Protease Inhibitors; Quinolones; RNA, Viral; Tenofovir | 2018 |
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; RNA, Viral; Semen; Semen Analysis; Tenofovir | 2019 |
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a m
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Tablets; Tenofovir | 2020 |
A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Topics: Alanine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Tenofovir | 2023 |
19 other study(ies) available for alanine and jtk-303
Article | Year |
---|---|
Tenofovir alafenamide for HIV infection: is less more?
Topics: Adenine; Alanine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2015 |
Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.
Topics: Adenine; Alanine; Animals; Delayed-Action Preparations; Disease Transmission, Infectious; Female; HIV Infections; Injections, Subcutaneous; Mice; Mice, SCID; Nanoparticles; Plasma; Quinolones; Tenofovir; Treatment Outcome; Vagina; Viral Load | 2017 |
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Pyridones; Quinolones; Raltegravir Potassium; Ritonavir; Tenofovir; Treatment Outcome | 2018 |
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Quinolones; Renal Insufficiency; Suicide, Attempted; Tenofovir | 2019 |
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report.
Topics: Adenine; Alanine; Cobicistat; Emtricitabine; HIV Infections; Humans; International Normalized Ratio; Quinolones; Tenofovir; Warfarin | 2019 |
Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Enteral Nutrition; Gastrostomy; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Sustained Virologic Response; Tablets; Tenofovir | 2019 |
Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; Cobicistat; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Quinolones; Sexual and Gender Minorities; Tenofovir; Time Factors; Young Adult | 2019 |
Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Quinolones; Tenofovir | 2020 |
Switching antiretrovirals in older patients.
Topics: Adenine; Aged; Alanine; Bone Density; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Fevers and Night Sweats in a 35-year-old Man With Recent Travel to Southeast Asia.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Asia, Southeastern; Cobicistat; Emtricitabine; HIV Infections; Humans; Laos; Male; Quinolones; Sweating; Tenofovir; Thailand; Travel; United States | 2019 |
Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Dyslipidemias; Emtricitabine; Female; HIV Seropositivity; Humans; Lipids; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Weight Gain | 2020 |
Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Mutation; Quinolones; Retrospective Studies; Tenofovir | 2020 |
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Quinolones; Tenofovir; Weight Gain | 2021 |
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Cohort Studies; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; Taiwan; Tenofovir | 2021 |
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Postoperative Complications; Quinolones; Tenofovir; Viral Load | 2020 |
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
Topics: Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Quinolones; Tenofovir; Young Adult | 2021 |
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cobicistat; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Quality of Life; Quinolones; Sleep Quality; Tenofovir | 2021 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |
Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques.
Topics: Alanine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Leukocytes, Mononuclear; Macaca; Tenofovir; Tissue Distribution | 2022 |